ProfoundBio, a Seattle-based biotech company on a mission to redefine cancer treatment, announced a $112 million Series B round.
According to Erin Lavelle, chief operating officer and chief financial officer at ProfoundBio, “This investment boosts our momentum, especially with three clinical-stage candidates in our portfolio and another poised for clinical trials in the next few months.”
The additional capital will support ProfoundBio’s clinical and preclinical antibody-drug conjugate programs, which primarily target tumor cancers.